TACE combined with sorafenib for inoperable hepatocellular carcinoma：analysis of treatment interval

VernacularTitle:TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析
Author: Xuesong YAO ; Dong YAN ; Huiying ZENG ; Dezhong LIU ; Huai LI
Publication Type:Journal Article
Keywords: hepatocellular carcinoma; hepatic artery; chemoembolization; sorafenib
From: Journal of Interventional Radiology 2014;(9):769-771
CountryChina
Language:Chinese
Abstract: Objective To investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with sorafenib for the treatment of inoperable hepatocellular carcinoma (HCC), and to discuss the influence of treatment interval on the survival time. Methods During the period from July 2008 to May 2011 at authors’ hospital, a total of 50 patients with inoperable HCC were treated with TACE together with sorafenib. The treatment intervals between each TACE procedure were recorded. The results were analyzed. Results Up to Dec. 31, 2011, the median follow-up time of the 50 patients was 310 days. The mean interval between TACE treatments was 69 days before the combination treatment was employed , while the mean interval was 112 days after the combination treatment started , and the longest interval was 648 days. Conclusion Combination treatment TACE with sorafenib can remarkably prolong the treatment interval in patients with inoperable HCC, thus the patient can get more survival benefits.